indications for semaglutide fda approved FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to Semaglutide Indication Opportunity: From CDK,

Data Availability Statement The data supporting this study are available upon request to the corresponding author

I had occasion to chat with the clinic twice, and the folks were polite, respectful, and answered all my questions satisfactorily

Studies show evidence of improvement in dilated cardiomyopathy (DCM) in Boxers with L-carnitine supplementation, though the positive results are inconsistent with other breeds with the same condition

Commonly reported side effects include: Nausea, vomiting, and diarrhoea particularly during dose escalation Constipation and abdominal discomfort Decreased appetite and early satiety Injection site reactions (mild and transient) Fatigue, especially in the initial weeks of treatment These gastrointestinal effects are consistent with the GLP-1 mechanism and are generally dose-dependent and transient

DAP, DJE, JBK and VMJ are stockholders of Pfizer Inc